Seems like a reasonable headline in this case given the content of the article.

But the potential for researchers to bias the outcomes of these trials has become a common critique of the psychedelic research field. It is unusual for a drug under F.D.A. consideration to also be used personally and recreationally by the researchers studying it, or even for clinical trial researchers and clinicians to be encouraged to test the drug themselves. But that’s exactly what Lykos has done with MDMA.